Lysophospholipid receptors in drug discovery

Experimental Cell Research

Volumn 333, Issue 2, 2015, Pages 171-177

  Kihara, Yasuyuki ^a   Mizuno, Hirotaka ^a,b   Chun, Jerold ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b ONO PHARMACEUTICAL CO   (Japan)

Author keywords

Cannabinoids; Fingolimod; FTY720; GPCR; Idiopathic pulmonary fibrosis; LPA; LPS; Multiple sclerosis; S1P

Indexed keywords

BMS 986202; FINGOLIMOD; G PROTEIN COUPLED RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDYLINOSITOL RECEPTOR; LYSOPHOSPHATIDYLSERINE; LYSOPHOSPHOLIPID RECEPTOR; RECEPTOR BLOCKING AGENT; SAR100842; SPHINGOSINE 1 PHOSPATE RECEPTOR; UNCLASSIFIED DRUG; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHOLIPID; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1-PHOSPHATE;

HUMAN; MULTIPLE SCLEROSIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DEVELOPMENT; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY;

ANIMALS; DRUG DISCOVERY; HUMANS; LYSOPHOSPHOLIPIDS; MOLECULAR TARGETED THERAPY; MULTIPLE SCLEROSIS; RECEPTORS, LYSOPHOSPHATIDIC ACID; RECEPTORS, LYSOSPHINGOLIPID; SIGNAL TRANSDUCTION; SPHINGOSINE;

EID: 84927909852     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2014.11.020     Document Type: Review

References (65)

1. Hammad S.M., Pierce J.S., Soodavar F., Smith K.J., Al Gadban M.M., Rembiesa B., Klein R.L., Hannun Y.A., Bielawski J., Bielawska A. Blood sphingolipidomics in healthy humans: impact of sample collection methodology. J. Lipid Res. 2010, 51:3074-3087.
2. Yung Y.C., Stoddard N.C., Chun J. LPA receptor signaling: pharmacology, physiology, and pathophysiology. J. Lipid Res. 2014, 55:1192-1214.
3. Shindou H., Hishikawa D., Harayama T., Yuki K., Shimizu T. Recent progress on acyl CoA: lysophospholipid acyltransferase research. J. Lipid Res. 2009, 50(Suppl.):S46-S51.
4. Maceyka M., Harikumar K.B., Milstien S., Spiegel S. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol. 2012, 22:50-60.
5. Shimizu T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu. Rev. Pharmacol. Toxicol. 2009, 49:123-150.
6. Vroling B., Sanders M., Baakman C., Borrmann A., Verhoeven S., Klomp J., Oliveira L., de Vlieg J., Vriend G. GPCRDB: information system for G protein-coupled receptors. Nucleic Acids Res. 2011, 39:D309-D319.
7. Choi J.W., Herr D.R., Noguchi K., Yung Y.C., Lee C.W., Mutoh T., Lin M.E., Teo S.T., Park K.E., Mosley A.N., Chun J. LPA receptors: subtypes and biological actions. Annu. Rev. Pharmacol. Toxicol. 2010, 50:157-186.
8. Kihara Y., Maceyka M., Spiegel S., Chun J. Lysophospholipid receptor nomenclature review: IUPHAR review 8. Br. J. Pharmacol. 2014, 171:3575-3594.
9. Makide K., Uwamizu A., Shinjo Y., Ishiguro J., Okutani M., Inoue A., Aoki J. Novel lysophosphoplipid receptors: their structure and function. J. Lipid Res. 2014, 55:1986-1995.
10. Klabunde T., Hessler G. Drug design strategies for targeting G-protein-coupled receptors. ChemBioChem: Eur. J. Chem. Biol. 2002, 3:928-944.
11. Lagerstrom M.C., Schioth H.B. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat. Rev. Drug Discov. 2008, 7:339-357.
12. Overington J.P., Al-Lazikani B., Hopkins A.L. How many drug targets are there?. Nat. Rev. Drug Discov. 2006, 5:993-996.
13. Mendelson K., Evans T., Hla T. Sphingosine 1-phosphate signalling. Development 2014, 141:5-9.
14. Yamashita A., Oka S., Tanikawa T., Hayashi Y., Nemoto-Sasaki Y., Sugiura T. The actions and metabolism of lysophosphatidylinositol, an endogenous agonist for GPR55. Prostaglandins Other Lipid Mediat. 2013, 107:103-116.
15. Hecht J.H., Weiner J.A., Post S.R., Chun J. Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J.Cell Biol. 1996, 135:1071-1083.
16. An S., Bleu T., Hallmark O.G., Goetzl E.J. Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J. Biol. Chem. 1998, 273:7906-7910.
17. Bandoh K., Aoki J., Hosono H., Kobayashi S., Kobayashi T., Murakami-Murofushi K., Tsujimoto M., Arai H., Inoue K. Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. J. Biol. Chem. 1999, 274:27776-27785.
18. Noguchi K., Ishii S., Shimizu T. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J. Biol. Chem. 2003, 278:25600-25606.
19. Kotarsky K., Boketoft A., Bristulf J., Nilsson N.E., Norberg A., Hansson S., Owman C., Sillard R., Leeb-Lundberg L.M., Olde B. Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes. J. Pharmacol. Exp. Ther. 2006, 318:619-628.
20. Lee C.W., Rivera R., Gardell S., Dubin A.E., Chun J. GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J. Biol. Chem. 2006, 281:23589-23597.
21. Pasternack S.M., von Kugelgen I., Al Aboud K., Lee Y.A., Ruschendorf F., Voss K., Hillmer A.M., Molderings G.J., Franz T., Ramirez A., Nurnberg P., Nothen M.M., Betz R.C. G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nat. Genet. 2008, 40:329-334.
22. Yung Y.C., Mutoh T., Lin M.E., Noguchi K., Rivera R.R., Choi J.W., Kingsbury M.A., Chun J. Lysophosphatidic acid signaling may initiate fetal hydrocephalus. Sci. Transl. Med. 2011, 3:99ra87.
23. Ye X., Hama K., Contos J.J., Anliker B., Inoue A., Skinner M.K., Suzuki H., Amano T., Kennedy G., Arai H., Aoki J., Chun J. LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. Nature 2005, 435:104-108.
24. Lin M.E., Rivera R.R., Chun J. Targeted deletion of LPA5 identifies novel roles for lysophosphatidic acid signaling in development of neuropathic pain. J. Biol. Chem. 2012, 287:17608-17617.
25. Hu J., Oda S.K., Shotts K., Donovan E.E., Strauch P., Pujanauski L.M., Victorino F., Al-Shami A., Fujiwara Y., Tigyi G., Oravecz T., Pelanda R., Torres R.M. Lysophosphatidic acid receptor 5 inhibits B cell antigen receptor signaling and antibody response. J. Immunol. 2014, 193:85-95.
26. Oda S.K., Strauch P., Fujiwara Y., Al-Shami A., Oravecz T., Tigyi G., Pelanda R., Torres R.M. Lysophosphatidic acid inhibits CD8 T cell activation and control of tumor progression. Cancer Immunol. Res. 2013, 1:245-255.
27. Yanagida K., Masago K., Nakanishi H., Kihara Y., Hamano F., Tajima Y., Taguchi R., Shimizu T., Ishii S. Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6. J. Biol. Chem. 2009, 284:17731-17741.
28. Shinkuma S., Akiyama M., Inoue A., Aoki J., Natsuga K., Nomura T., Arita K., Abe R., Ito K., Nakamura H., Ujiie H., Shibaki A., Suga H., Tsunemi Y., Nishie W., Shimizu H. Prevalent LIPH founder mutations lead to loss of P2Y5 activation ability of PA-PLA1alpha in autosomal recessive hypotrichosis. Hum. Mutat. 2010, 31:602-610.
29. Hla T., Maciag T. An abundant transcript induced in differentiating human endothelial cells encodes a polypeptide with structural similarities to G-protein-coupled receptors. J. Biol. Chem. 1990, 265:9308-9313.
30. Lee M.J., Van Brocklyn J.R., Thangada S., Liu C.H., Hand A.R., Menzeleev R., Spiegel S., Hla T. Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science 1998, 279:1552-1555.
31. An S., Bleu T., Huang W., Hallmark O.G., Coughlin S.R., Goetzl E.J. Identification of cDNAs encoding two G protein-coupled receptors for lysosphingolipids. FEBS Lett. 1997, 417:279-282.
32. Im D.S., Heise C.E., Ancellin N., O'Dowd B.F., Shei G.J., Heavens R.P., Rigby M.R., Hla T., Mandala S., McAllister G., George S.R., Lynch K.R. Characterization of a novel sphingosine 1-phosphate receptor, Edg-8. J. Biol. Chem. 2000, 275:14281-14286.
33. Yamazaki Y., Kon J., Sato K., Tomura H., Sato M., Yoneya T., Okazaki H., Okajima F., Ohta H. Edg-6 as a putative sphingosine 1-phosphate receptor coupling to Ca(2+) signaling pathway. Biochem. Biophys. Res. Commun. 2000, 268:583-589.
34. Liu Y., Wada R., Yamashita T., Mi Y., Deng C.X., Hobson J.P., Rosenfeldt H.M., Nava V.E., Chae S.S., Lee M.J., Liu C.H., Hla T., Spiegel S., Proia R.L. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J. Clin. Investig. 2000, 106:951-961.
35. Spiegel S., Milstien S. The outs and the ins of sphingosine-1-phosphate in immunity. Nat. Rev. Immunol. 2011, 11:403-415.
36. Green J.A., Suzuki K., Cho B., Willison L.D., Palmer D., Allen C.D., Schmidt T.H., Xu Y., Proia R.L., Coughlin S.R., Cyster J.G. The sphingosine 1-phosphate receptor S1P(2) maintains the homeostasis of germinal center B cells and promotes niche confinement. Nat. Immunol. 2011, 12:672-680.
37. Ishii I., Friedman B., Ye X., Kawamura S., McGiffert C., Contos J.J., Kingsbury M.A., Zhang G., Brown J.H., Chun J. Selective loss of sphingosine 1-phosphate signaling with no obvious phenotypic abnormality in mice lacking its G protein-coupled receptor, LP(B3)/EDG-3. J. Biol. Chem. 2001, 276:33697-33704.
38. Ishii I., Ye X., Friedman B., Kawamura S., Contos J.J., Kingsbury M.A., Yang A.H., Zhang G., Brown J.H., Chun J. Marked perinatal lethality and cellular signaling deficits in mice null for the two sphingosine 1-phosphate (S1P) receptors, S1P(2)/LP(B2)/EDG-5 and S1P(3)/LP(B3)/EDG-3. J. Biol. Chem. 2002, 277:25152-25159.
39. Jaillard C., Harrison S., Stankoff B., Aigrot M.S., Calver A.R., Duddy G., Walsh F.S., Pangalos M.N., Arimura N., Kaibuchi K., Zalc B., Lubetzki C. Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival. J. Neurosci.: Off. J. Soc. Neurosci. 2005, 25:1459-1469.
40. Novgorodov A.S., El-Alwani M., Bielawski J., Obeid L.M., Gudz T.I. Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration. FASEB J.: Off. Publ. Fed. Am. Soc. Exp. Biol. 2007, 21:1503-1514.
41. Oka S., Nakajima K., Yamashita A., Kishimoto S., Sugiura T. Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem. Biophys. Res. Commun. 2007, 362:928-934.
42. Sugo T., Tachimoto H., Chikatsu T., Murakami Y., Kikukawa Y., Sato S., Kikuchi K., Nagi T., Harada M., Ogi K., Ebisawa M., Mori M. Identification of a lysophosphatidylserine receptor on mast cells. Biochem. Biophys. Res. Commun. 2006, 341:1078-1087.
43. Kitamura H., Makide K., Shuto A., Ikubo M., Inoue A., Suzuki K., Sato Y., Nakamura S., Otani Y., Ohwada T., Aoki J. GPR34 is a receptor for lysophosphatidylserine with a fatty acid at the sn-2 position. J. Biochem. 2012, 151:511-518.
44. Inoue A., Ishiguro J., Kitamura H., Arima N., Okutani M., Shuto A., Higashiyama S., Ohwada T., Arai H., Makide K., Aoki J. TGFalpha shedding assay: an accurate and versatile method for detecting GPCR activation. Nat. Methods 2012, 9:1021-1029.
45. Adachi K., Chiba K. FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology. Perspect. Med. Chem. 2008, 1:11-23.
46. Brinkmann V., Davis M.D., Heise C.E., Albert R., Cottens S., Hof R., Bruns C., Prieschl E., Baumruker T., Hiestand P., Foster C.A., Zollinger M., Lynch K.R. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. 2002, 277:21453-21457.
47. Mandala S., Hajdu R., Bergstrom J., Quackenbush E., Xie J., Milligan J., Thornton R., Shei G.J., Card D., Keohane C., Rosenbach M., Hale J., Lynch C.L., Rupprecht K., Parsons W., Rosen H. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002, 296:346-349.
48. Paugh S.W., Payne S.G., Barbour S.E., Milstien S., Spiegel S. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett. 2003, 554:189-193.
49. Matloubian M., Lo C.G., Cinamon G., Lesneski M.J., Xu Y., Brinkmann V., Allende M.L., Proia R.L., Cyster J.G. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004, 427:355-360.
50. Graler M.H., Goetzl E.J. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J.: Off. Publ. Fed. Am. Soc. Exp. Biol. 2004, 18:551-553.
51. Oo M.L., Thangada S., Wu M.T., Liu C.H., Macdonald T.L., Lynch K.R., Lin C.Y., Hla T. Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J. Biol. Chem. 2007, 282:9082-9089.
52. Webb M., Tham C.S., Lin F.F., Lariosa-Willingham K., Yu N., Hale J., Mandala S., Chun J., Rao T.S. Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J. Neuroimmunol. 2004, 153:108-121.
53. Salvadori M., Budde K., Charpentier B., Klempnauer J., Nashan B., Pallardo L.M., Eris J., Schena F.P., Eisenberger U., Rostaing L., Hmissi A., Aradhye S., Group F.T.Y.S. FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am. J. Transplant.: Off. J. Am. Soc. Transplant Am. Soc. Transpl. Surg. 2006, 6:2912-2921.
54. Kappos L., Antel J., Comi G., Montalban X., O'Connor P., Polman C.H., Haas T., Korn A.A., Karlsson G., Radue E.W., Group F.D.S. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 2006, 355:1124-1140.
55. Groves A., Kihara Y., Chun J. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J. Neurol. Sci. 2013, 328:9-18.
56. Calabresi P.A., Radue E.W., Goodin D., Jeffery D., Rammohan K.W., Reder A.T., Vollmer T., Agius M.A., Kappos L., Stites T., Li B., Cappiello L., von Rosenstiel P., Lublin F.D. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014, 13:545-556.
57. Gilenya Sales Data from Drugs.com (Updated: 2014 February; Cited: 2014 October). Available from:. http://www.drugs.com/stats/gilenya.
58. Rommer P.S., Zettl U.K., Kieseier B., Hartung H.P., Menge T., Frohman E., Greenberg B.M., Hemmer B., Stuve O. Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. Clin. Exp. Immunol. 2014, 175:397-407.
59. Gross T.J., Hunninghake G.W. Idiopathic pulmonary fibrosis. N. Engl. J.Med. 2001, 345:517-525.
60. Tager A.M., LaCamera P., Shea B.S., Campanella G.S., Selman M., Zhao Z., Polosukhin V., Wain J., Karimi-Shah B.A., Kim N.D., Hart W.K., Pardo A., Blackwell T.S., Xu Y., Chun J., Luster A.D. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat. Med. 2008, 14:45-54.
61. Swaney J.S., Chapman C., Correa L.D., Stebbins K.J., Bundey R.A., Prodanovich P.C., Fagan P., Baccei C.S., Santini A.M., Hutchinson J.H., Seiders T.J., Parr T.A., Prasit P., Evans J.F., Lorrain D.S. A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. Br. J. Pharmacol. 2010, 160:1699-1713.
62. Pattanaik D., Postlethwaite A.E. A role for lysophosphatidic acid and sphingosine 1-phosphate in the pathogenesis of systemic sclerosis. Discov. Med. 2010, 10:161-167.
63. Tokumura A., Carbone L.D., Yoshioka Y., Morishige J., Kikuchi M., Postlethwaite A., Watsky M.A. Elevated serum levels of arachidonoyl-lysophosphatidic acid and sphingosine 1-phosphate in systemic sclerosis. Int. J. Med. Sci. 2009, 6:168-176.
64. Castelino F.V., Seiders J., Bain G., Brooks S.F., King C.D., Swaney J.S., Lorrain D.S., Chun J., Luster A.D., Tager A.M. Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma. Arthr. Rheum. 2011, 63:1405-1415.
65. C.P.D. Dinesh Khanna, Alexandre JagerschmidtMartine Jasson, Oliver Distler and Yannick Allanore, SAR100842, an antagonist of lysophaphatidic acid receptor 1, as a potential treatment for patients with systemic sclerosis: results from a phase 2a study, American College of Rheumatology Annual Meeting Abstract #876 (2014).